Current controversies and challenges in allergic rhinitis management

David Price, Pete Smith, Peter Hellings, Nikos Papadopoulos, Wytske Fokkens, Antonella Muraro, Ruth Murray, Alison Chisholm, Pascal Demoly, Glenis Scadding, Joaquim Mullol, Phil Lieberman, Claus Bachert, Ralph Mösges, Dermot Ryan, Jean Bousquet

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

There are many obstacles in the path of effective allergy management, in general, and allergic rhinitis (AR) control, in particular. Chief among them are: insufficient symptom relief in some patients provided by some currently considered first-line AR treatments in real life; an over-reliance on randomized controlled trials to direct AR guideline recommendations; the need for a broader interpretation of the AR evidence base (to include randomized controlled trials and real-life studies); poorly designed and interpreted studies; and lack of an AR control concept and common language of control. These controversies are fully reviewed here and challenging solutions have been presented.

Original languageEnglish
Pages (from-to)1205-1217
Number of pages13
JournalExpert Review of Clinical Immunology
Volume11
Issue number11
Early online date29 Aug 2015
DOIs
Publication statusPublished - 1 Sep 2015

Fingerprint

Randomized Controlled Trials
Hypersensitivity
Language
Allergic Rhinitis
Guidelines
Therapeutics

Keywords

  • allergic rhinitis
  • clinical relevance
  • control
  • guidelines
  • randomized controlled trials
  • real life

Cite this

Price, D., Smith, P., Hellings, P., Papadopoulos, N., Fokkens, W., Muraro, A., ... Bousquet, J. (2015). Current controversies and challenges in allergic rhinitis management. Expert Review of Clinical Immunology , 11(11), 1205-1217. https://doi.org/10.1586/1744666X.2015.1081814

Current controversies and challenges in allergic rhinitis management. / Price, David; Smith, Pete; Hellings, Peter; Papadopoulos, Nikos; Fokkens, Wytske; Muraro, Antonella; Murray, Ruth; Chisholm, Alison; Demoly, Pascal; Scadding, Glenis; Mullol, Joaquim; Lieberman, Phil; Bachert, Claus; Mösges, Ralph; Ryan, Dermot; Bousquet, Jean.

In: Expert Review of Clinical Immunology , Vol. 11, No. 11, 01.09.2015, p. 1205-1217.

Research output: Contribution to journalArticle

Price, D, Smith, P, Hellings, P, Papadopoulos, N, Fokkens, W, Muraro, A, Murray, R, Chisholm, A, Demoly, P, Scadding, G, Mullol, J, Lieberman, P, Bachert, C, Mösges, R, Ryan, D & Bousquet, J 2015, 'Current controversies and challenges in allergic rhinitis management', Expert Review of Clinical Immunology , vol. 11, no. 11, pp. 1205-1217. https://doi.org/10.1586/1744666X.2015.1081814
Price, David ; Smith, Pete ; Hellings, Peter ; Papadopoulos, Nikos ; Fokkens, Wytske ; Muraro, Antonella ; Murray, Ruth ; Chisholm, Alison ; Demoly, Pascal ; Scadding, Glenis ; Mullol, Joaquim ; Lieberman, Phil ; Bachert, Claus ; Mösges, Ralph ; Ryan, Dermot ; Bousquet, Jean. / Current controversies and challenges in allergic rhinitis management. In: Expert Review of Clinical Immunology . 2015 ; Vol. 11, No. 11. pp. 1205-1217.
@article{dfb33e241fef46b9ae76aa8f18796e7a,
title = "Current controversies and challenges in allergic rhinitis management",
abstract = "There are many obstacles in the path of effective allergy management, in general, and allergic rhinitis (AR) control, in particular. Chief among them are: insufficient symptom relief in some patients provided by some currently considered first-line AR treatments in real life; an over-reliance on randomized controlled trials to direct AR guideline recommendations; the need for a broader interpretation of the AR evidence base (to include randomized controlled trials and real-life studies); poorly designed and interpreted studies; and lack of an AR control concept and common language of control. These controversies are fully reviewed here and challenging solutions have been presented.",
keywords = "allergic rhinitis, clinical relevance, control, guidelines, randomized controlled trials, real life",
author = "David Price and Pete Smith and Peter Hellings and Nikos Papadopoulos and Wytske Fokkens and Antonella Muraro and Ruth Murray and Alison Chisholm and Pascal Demoly and Glenis Scadding and Joaquim Mullol and Phil Lieberman and Claus Bachert and Ralph M{\"o}sges and Dermot Ryan and Jean Bousquet",
year = "2015",
month = "9",
day = "1",
doi = "10.1586/1744666X.2015.1081814",
language = "English",
volume = "11",
pages = "1205--1217",
journal = "Expert Review of Clinical Immunology",
issn = "1744-666X",
publisher = "Expert Reviews Ltd.",
number = "11",

}

TY - JOUR

T1 - Current controversies and challenges in allergic rhinitis management

AU - Price, David

AU - Smith, Pete

AU - Hellings, Peter

AU - Papadopoulos, Nikos

AU - Fokkens, Wytske

AU - Muraro, Antonella

AU - Murray, Ruth

AU - Chisholm, Alison

AU - Demoly, Pascal

AU - Scadding, Glenis

AU - Mullol, Joaquim

AU - Lieberman, Phil

AU - Bachert, Claus

AU - Mösges, Ralph

AU - Ryan, Dermot

AU - Bousquet, Jean

PY - 2015/9/1

Y1 - 2015/9/1

N2 - There are many obstacles in the path of effective allergy management, in general, and allergic rhinitis (AR) control, in particular. Chief among them are: insufficient symptom relief in some patients provided by some currently considered first-line AR treatments in real life; an over-reliance on randomized controlled trials to direct AR guideline recommendations; the need for a broader interpretation of the AR evidence base (to include randomized controlled trials and real-life studies); poorly designed and interpreted studies; and lack of an AR control concept and common language of control. These controversies are fully reviewed here and challenging solutions have been presented.

AB - There are many obstacles in the path of effective allergy management, in general, and allergic rhinitis (AR) control, in particular. Chief among them are: insufficient symptom relief in some patients provided by some currently considered first-line AR treatments in real life; an over-reliance on randomized controlled trials to direct AR guideline recommendations; the need for a broader interpretation of the AR evidence base (to include randomized controlled trials and real-life studies); poorly designed and interpreted studies; and lack of an AR control concept and common language of control. These controversies are fully reviewed here and challenging solutions have been presented.

KW - allergic rhinitis

KW - clinical relevance

KW - control

KW - guidelines

KW - randomized controlled trials

KW - real life

U2 - 10.1586/1744666X.2015.1081814

DO - 10.1586/1744666X.2015.1081814

M3 - Article

VL - 11

SP - 1205

EP - 1217

JO - Expert Review of Clinical Immunology

JF - Expert Review of Clinical Immunology

SN - 1744-666X

IS - 11

ER -